5CV.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:35):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
Dagens volum	158 231
Gjennomsnittsvolum	77 966.00
Markedsverdi	486.27M
EPS	€-0.217 ( 2023-09-30 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.480
ATR14	€0.0110 (0.51%)

Volum Korrelasjon

Lang: -0.07 (neutral)

Kort: 0.59 (weak)

Signal:(36.222) Neutral

CureVac N.V. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

CureVac N.V. Korrelasjon - Valuta/Råvare

0.06
( neutral )

0.11
( neutral )

0.00
( neutral )

-0.42
( neutral )

0.00
( neutral )

0.52
( weak )

CureVac N.V. Økonomi

Annual	2023
Omsetning:	€52.70M
Bruttogevinst:	€-268.58M (-509.67 %)
EPS:	€0

FY	2023
Omsetning:	€52.70M
Bruttogevinst:	€-268.58M (-509.67 %)
EPS:	€0

FY	2022
Omsetning:	€67.42M
Bruttogevinst:	€-116.57M (-172.91 %)
EPS:	€-1.320

FY	2021
Omsetning:	€102.99M
Bruttogevinst:	€-135.21M (-131.28 %)
EPS:	€-2.34

Financial Reports:

No articles found.

CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.